Gilteritinib Professional Medication Guide & Dosage Management

　　Gilteritinib is a targeted therapy designed for specific genetic mutations.To ensure safety and efficacy,patients must take this medication under the strict supervision of a hematologist or oncologist.Close follow-up and individualized management are essential.In the event of severe adverse reactions,treatment interruption or dose adjustments may be required.

　　1.Patient Selection and Prerequisites

　　Before initiating Gilteritinib therapy,patients must have the presence of an FLT3 mutation confirmed in their blood or bone marrow using an internationally approved test(e.g.,FDA-approved).A confirmed genetic testing result is a mandatory prerequisite for using this medication.

　　2.Recommended Dosage and Daily Administration

　　Standard Dose and Duration:The recommended starting dose is 120mg taken orally once daily.It can be taken with or without food.Since clinical responses may be delayed,it is recommended to continue treatment for at least 6 months to adequately assess the response,provided there is no disease progression and no unacceptable toxicity.

　　Proper Administration:Gilteritinib tablets must be swallowed whole with water.Do not break,crush,or chew the tablets.To maintain stable blood concentration,the medication should be taken at approximately the same time each day.

　　Missed Dose Protocol:If a dose is missed,it should be taken as soon as possible on the same day.However,ensure there is at least a 12-hour interval between the missed dose and the next scheduled dose.Resume the regular schedule the following day;never take two doses within a 12-hour window.

　　3.Treatment Monitoring and Dose Adjustment Strategies

　　Routine Clinical Monitoring:Strict monitoring is required before and during treatment.Complete blood counts and blood chemistry(including creatine phosphokinase)should be checked at least weekly in month 1,every two weeks in month 2,and monthly thereafter.Electrocardiograms(ECG)must be performed before treatment,on days 8 and 15 of cycle 1,and prior to the start of the next two cycles.

　　Differentiation Syndrome Management:If differentiation syndrome is suspected,immediately administer systemic corticosteroids(e.g.,Dexamethasone 10mg IV every 12 hours or equivalent)for at least 3 days,alongside hemodynamic monitoring.If severe symptoms persist beyond 48 hours of steroid therapy,interrupt Gilteritinib until symptoms improve to grade 2 or below before resuming.

　　Posterior Reversible Encephalopathy Syndrome(PRES):If PRES is confirmed via brain magnetic resonance imaging(MRI),Gilteritinib must be permanently discontinued.

　　QTc Prolongement Management:If QTcF exceeds 500 msec,interrupt treatment.Resume at 80mg once daily when QTcF returns to within 30 msec of baseline or drops to 480 msec or below.If the day 8 ECG in cycle 1 shows a QTc increase of>30 msec from baseline,repeat the ECG on day 9 and consider reducing the dose to 80mg daily if confirmed.

　　Pancreatitis and Other Severe Toxicities:In cases of pancreatitis or any other grade 3 or higher treatment-related toxicity,interrupt Gilteritinib immediately.Once pancreatitis resolves or other toxicities improve to grade 1 or below,restart treatment at a reduced dose of 80mg once daily.